Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2025 | Chidamide plus toripalimab shows promise in advanced sarcoma

Xing Zhang, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses results from a Phase II trial (NCT04025931) of chidamide, an oral histone deacetylase inhibitor, with toripalimab in patients with advanced sarcoma after standard therapy failure. The combination was well tolerated, with most adverse events being grade 1–2. Encouraging activity was observed across subtypes, particularly in well/dedifferentiated liposarcoma, where response rates and progression-free survival were notably improved compared to other sarcoma types. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.